ForumIAS LATEST
- SFG FRC 2027 | Program starts from 19th Dec. 2026 | Admissions open for Entrance Test Click Here to know more →
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →
Source– This post is based on the article “Breakthrough Nutraceutical ‘AKTOCYTE’ by the Department of Atomic Energy Set to Transform Cancer Care” published in “PIB” on 13th December 2023.
Why in the News?
AKTOCYTE tablets have been granted approval by the Food Safety and Standards Authority of India (FSSAI).
What are AKTOCYTE tablets?
| Specifications | Details |
| What is it? | Its a tablet used during cancer treatment to minimize the side effects of radiotherapy. |
| Developed by | Department of Atomic Energy and M/s. IDRS Labs Pvt. Ltd. Bengaluru |
| Characteristics | 1) Impressive Recovery in Pelvic Cancer: AKTOCYTE Tablets show promise in pelvic cancer patients suffering from radiotherapy-induced Cystitis (Blood in urine). 2) Versatile AKTOCYTE Tablets: Beyond a supplement, they serve as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant, highlighting their diverse applications in cancer care. 3) Safe: AKTOCYTE has received approval from the FSSAI. |
| Market Entry | AKTOCYTE Tablets, set to debut in January 2024, promise to revolutionize cancer treatment protocols. |
What is FSSAI?
1) Food Safety and Standards Authority of India (FSSAI) is a statutory body established under the Food Safety and Standards Act, 2006 (FSS Act).
2) FSSAI is an autonomous body under the Ministry of Health & Family Welfare.
| For more information on FSSAI Click Here to Read |
UPSC Syllabus- Science & Technology
